SCHEMBL3866402

SCHEMBL3866402

C#CC(N)CC(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
ALDH1A1 P00352 7/20 0.40
TRPA1 O75762 1/20 0.40
LMNA P02545 2/20 0.39
CYP2D6 P10635 2/20 0.39
NFKB1 P19838 1/20 0.39
MAPT P10636 1/20 0.39
CYP1A2 P05177 1/20 0.39
ALOX15 P16050 3/20 0.38
ITGB3 P05106 1/20 0.38
ITGA2B P08514 1/20 0.38
CYP3A4 P08684 2/20 0.38
TSHR P16473 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
HSD17B10 Q99714 2/20 0.37
CHRM1 P11229 1/20 0.37
ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778348 1.00 MGAM (0.43) MGAMGAASIMGAM2ALDH1A1
SCHEMBL6779221 1.00 MGAM (0.43) MGAMGAASIMGAM2ALDH1A1
Hydrochloric Acid SCHEMBL6778529 0.98 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1
Hydrochloric Acid SCHEMBL6776386 0.98 MGAM (0.41) MGAMGAASIMGAM2ALDH1A1
Hydrochloric Acid SCHEMBL27348020 0.84 SOAT1 (0.45) MGAMGAASIMGAM2ALDH1A1
SCHEMBL7355051 0.80 GAA (0.43) MGAMGAASIMGAM2ALDH1A1
Water SCHEMBL10517713 0.80 GAA (0.43) MGAMGAASIMGAM2ALDH1A1
Hydrochloric Acid SCHEMBL10896652 0.79 LMNA (0.53) MGAMGAASIMGAM2ALDH1A1
SCHEMBL18072538 0.79
Hydrochloric Acid SCHEMBL28574643 0.78 LMNA (0.41) MGAMGAASIMGAM2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6214609-B1 CONTACTING RACEMIC BETA AMINO ACID OR ITS ESTER WITH AN ACYL DONOR AND ENZYME UNDER CONDITIONS OT ACYLATE ONE ENANTIOMER TO ITS N-ACYLATED DERIVATIVE MONSANTO COMPANY 2001-04-10 US claimed
EP-0839128-B1 PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE SEARLE & CO (US) 2000-04-05 EP claimed
EP-0979303-A1 METHOD AND APPARATUS FOR PREPARATION OF CHIRAL BETA AMINO ACIDS G.D. SEARLE & CO. (US) 2000-02-16 EP claimed
WO-1998050575-A1 METHOD AND APPARATUS FOR PREPARATION OF CHIRAL BETA AMINO ACIDS G.D. SEARLE & CO. (US) 1998-11-12 WO claimed
EP-0839128-A1 PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE G.D. SEARLE & CO. (US) 1998-05-06 EP claimed
WO-1997003947-A1 PROCESS FOR THE PREPARATION OF ETHYL 3S-[[4-[[4-(AMINOIMINOMETHYL)PHENYL]AMINO]-1,4-DIOXOBUTYL]AMINO]-4-PENTYNOATE G.D. SEARLE & CO. (US) 1997-02-06 WO claimed
US-10717704-B2 Inhibitors of creatine transport and uses thereof RGENIX, INC. (US) 2020-07-21 US disclosed
US-20190315680-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF INSPIRNA, INC. 2019-10-17 US disclosed
US-20170050924-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF INSPIRNA, INC. 2017-02-23 US disclosed
EP-1047425-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2009-04-22 EP disclosed
US-6902927-B2 Enzymatic process for the enantiomeric resolution of amino acids AVENTIS PHARMA S.A. (FR) 2005-06-07 US disclosed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
CN-1134423-C Adhesion receptor antagonists ס�ѻ�ѧ��ҵ��ʽ���� 2004-01-14 CN disclosed
EP-0691953-A1 1-AMIDINOPHENYL-PYRROLIDONES PIPERIDINONES AZETINONES AS PLATELET AGGREGATION INHIBITORS G.D. SEARLE & CO. (US) 1996-01-17 EP disclosed
WO-1994022820-A1 1-AMIDINOPHENYL-PYRROLIDONES PIPERIDINONES AZETINONES AS PLATELET AGGREGATION INHIBITORS G.D. SEARLE & CO. (US) 1994-10-13 WO disclosed
EP-0614360-A1 SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. SEARLE & CO (US) 1994-09-14 EP disclosed
US-5344957-A Amidinoiphenyl-substituted G.D. SEARLE & CO. (US) 1994-09-06 US disclosed
US-5239113-A Anticoagulants MONSANTO COMPANY (US) 1993-08-24 US disclosed
EP-0542708-A1 Substituted B-amino acid derivatives useful as platelet aggregation inhibitors MONSANTO COMPANY (US) 1993-05-19 EP disclosed
WO-1993007867-A1 SUBSTITUTED β-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS G.D. SEARLE & CO. (US) 1993-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717704-B2 Inhibitors of creatine transport and uses thereof CKMT1A; CKMT1B, SLC25A1, SLC2A1 MGAM 873/4885GAA 548/4885SI 1407/4885
US-20170050924-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF CKMT1A; CKMT1B, SLC25A1, SLC2A1 MGAM 873/4885GAA 548/4885SI 1407/4885
US-20190315680-A1 INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF CKMT1A; CKMT1B, SLC25A1, SLC2A1 MGAM 873/4885GAA 548/4885SI 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.